Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... MDS/CMML (defined as ≥ 10% peripheral blood or marrow blasts and/or IPSS score ≥ 1.5) and relapsed or refractory to ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  2. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... Disease status: remission or <10% bone marrow blasts Myelodysplasia Acute lymphoblastic leukemia Disease status: ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  3. Phase I, Dose Escalation Study of Decitabine

    ... (CR) following allo-HSCT ( bone marrow leukemic blasts less than 5% by morphology ), with high risk features ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  4. Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

    ... syndrome (MDS) (defined as having >/= 10% blasts in the bone marrow ) or patients with Chronic Myelomonocytic Leukemia (CMML) (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with Principal ...

    Clinical Trial last updated 05/23/2016 - 3:37pm.

  5. FAQs

    ... cells in your bone marrow being young white blood cells ( blasts ). About 30 out of 100 people with MDS will develop AML. Certain ... you have 3. Percentage of young white blood cells ( blasts ) in your bone marrow. 4. The number of cytogenetic changes you ...

    Topic section last updated 03/02/2016 - 11:42am.

  6. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... Must be in remission by morphology (<5% blasts ). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  7. Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

    ... adult patients with pathologically confirmed MDS (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 05/03/2016 - 9:46am.

  8. Allo HSCT Using RIC for Hematological Diseases

    ... be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a ... <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  9. MDS—The Past 40 Years. A Look at the Emerging Awareness and Classification of Myelodysplastic Syndromes.

    ... CMML) and refractory anemia with excess blasts (RAEB) that could be confused with acute leukemia. These conditions ... until the end of the century. Based on the percentage of blasts (young, immature blood cells) in bone marrow and blood, the FAB ...

    Page last updated 10/19/2015 - 2:29pm.

  10. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... or morphologic complete remission or MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating ...

    Clinical Trial last updated 05/02/2016 - 11:06am.